Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628849 | 0.83 | GAA (0.36) | ALDH3A1GAAHTTL3MBTL1LMNA | |
| SCHEMBL2928345 | 0.82 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL2927942 | 0.76 | HTR6 (0.40) | LMNAACLY | |
| SCHEMBL2926901 | 0.68 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL2925451 | 0.67 | CA12 (0.48) | PTGS2PTGS1ACLY | |
| SCHEMBL2927000 | 0.66 | PTGS2 (0.45) | PTGS2PTGS1PTGDR2 | |
| SCHEMBL2929240 | 0.65 | CDK5 (0.43) | SYK | |
| SCHEMBL2924094 | 0.65 | PTGS2 (0.67) | PTGS2ACLY | |
| SCHEMBL5152410 | 0.64 | PDPK1 (0.53) | PTGS2PTGS1 | |
| SCHEMBL2925592 | 0.64 | CA12 (0.42) | GAAHTTLMNAACLYNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673797-B1 | CYCLOOXYGENASE-2 INHIBITORS; TREATING INFLAMMATORY DISEASE INDUCED BY CYCLOOXYGENASE-2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-06 | — | — | US | claimed |
| EP-1086950-A1 | HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-03-28 | — | — | EP | claimed |
| EP-1086950-B1 | HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-7612070-B2 | Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612070-B2 | Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20050137202-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-06-23 | — | — | US | disclosed |
| US-6875770-B2 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040067964-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-08 | — | — | US | disclosed |
| US-6673797-B1 | CYCLOOXYGENASE-2 INHIBITORS; TREATING INFLAMMATORY DISEASE INDUCED BY CYCLOOXYGENASE-2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1086950-A1 | HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137202-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | PTGS2, IDO2, IDO1 | ALDH3A1 360/4885GAA 4084/4885HTT 1359/4885 |
| US-20040067964-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | IDO1, PTGS1, IDO2 | ALDH3A1 351/4885GAA 4424/4885HTT 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.